This phase III trial is evaluating pembrolizumab in patients who have previously received systemic treatment for advanced hepatocellular (liver) cancer.
This trial is treating patients with Hepatocellular (Liver) Cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma
This is a study of pembrolizumab (MK-3475) in participants with previously systemically treated advanced hepatocellular carcinoma (HCC).The primary objectives of this study are to determine 1) Progression-Free Survival (PFS) and 2) Overall Survival (OS) of pembrolizumab plus best supportive care (BSC) compared with placebo plus BSC. The primary hypotheses of this study are: 1) pembrolizumab plus BSC prolongs PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, assessed by a blinded central imaging vendor compared to placebo plus BSC, and 2) pembrolizumab plus BSC improves OS compared with placebo plus BSC.
Recruiting Hospitals Read More